A new drug for ALK-positive lung cancer approved today

The FDA has approved a new drug for patients with ALK-positive lung cancer. The drug is called brigatinib (brand name: Alunbrig) and is approved for treatment of patients whose tumor has the ALK mutation. Brigatinib is to be used after another drug targeting ALK stops working. The FDA press release is here: fda.gov/Drugs/InformationOn.... This is great news as it gives patients with the ALK mutation another treatment option.


Featured Content

Are you a patient with lung cancer?

Please add your voice as an advocate today to help raise awareness about some of the issues commonly faced.

Learn more

Featured by HealthUnlocked

3 Replies

  • This is the 8th new treatment approved in the last 2 years. It's an exciting time to be an advocate.

  • This is terrific news!!! Thanks for sharing!

  • Keep the good news coming, Mary!

You may also like...